Meet up with us at Booth 531 or at multiple talks and presentations throughout the meeting!

We are hiring! Open positions include a Director of Evidence Synthesis and Health Economist. See our careers page to learn more.

Peterson Health Technology Institute just released a first-of-its-kind digital health value assessment report on the value of digital diabetes management tools. PHTI is an independent assessment organization that worked with evaluation partners, clinical advisors, people with Type 2 diabetes, and other stakeholders during the assessment.

Curta assessed the clinical and budget economic impact of these technologies using the published ICER-PHTI Assessment Framework for Digital Health Technologies, including a systematic literature review and budget impact assessment.

Seeking multiple positions to join our team, including a Director of Evidence Synthesis!

Happy New Year! We are excited about what 2024 has in store.

An article co-authored by Sean D. Sullivan, Curta Partner and President, was one of three manuscripts selected by the PhRMA foundation that explore crucial challenges facing the CMS in implementing Medicare drug price negotiation.

This cost-effectiveness analysis of nirmatrelvir/ritonavir (NMV/r) vs. best supportive care for treating mild-to-moderate COVID-19 in high-risk patients found that NMV/r reduced hospitalizations (-0.027 per infected case), increased quality-adjusted life years (+0.030), decreased hospitalization costs (-$1,110), and increased total treatment cost (+$271), resulting in an incremental cost-effectiveness ratio of $8,931/QALY.

This budget impact analysis of nirmatrelvir/ritonavir (NMV/r) for treating mild-to-moderate COVID-19 at high-risk of severe disease found that NMV/r reduced the number of hospitalizations by 647 with a total budget impact of $2,733,745 ($0.23 PMPM). NMV/r was cost saving when including post-COVID conditions with a -$1,510,780 total budget impact (PMPM -$0.13).

The U.S. Inflation Reduction Act enabled CMS to negotiate Medicare drug prices. In this commentary, we outline the first ten drug selections, initial pricing methods, and the consideration of therapeutic alternatives and cost-effectiveness. While an implicit value framework is emerging, uncertainties persist, making CMS's role in shaping a national value framework for drug pricing unclear.

This meta-analysis of 224 studies on colorectal cancer (CRC) reveals a 4.1% HER2 positivity (HER2+) rate, with higher prevalence in RAS wild type (WT) CRC (6.1%). The enrichment of HER2+ CRC in microsatellite stable and left-sided CRC is confirmed. These findings support the need for routine HER2 testing in CRC, especially in RAS-WT and left-sided cases, given the clinical effectiveness of emerging HER2-targeted therapies in mCRC.

Curta was selected to bring our decades of experience in HEOR to an initiative of the Peterson Health Technology Institute (PHTI) to conduct evidence-based assessments of the clinical benefits and economic impact of digital health solutions.

Seeking HEOR researchers to join our team!

In this worked example using Curta’s Oncology Simulation Model (OSM) framework, Curta researchers examined the true overall population-level survival of avelumab as first line maintenance treatment option in metastatic urothelial carcinoma, considering that some patients with lack of response to chemotherapy or quick progression do not make it to maintenance at all. Findings can serve as a benchmark to compare a chemotherapy ± maintenance pathway to an alternative first line treatment strategy.

Curta partners Sean Sullivan, Josh Carlson, and David Veenstra and colleagues released a joint statement in reaction to the H.R. 485 legislation, a rule which may end up shaping health economics in the United States in important ways. “While the QALY remains controversial, placing value on both life extension and quality of life should not be.”

Using a mathematical model and clinical trial data, Curta investigators estimated for the year 2031 the effect of using A+CHP (brentuximab vedotin, cyclophosphamide, doxorubicin, prednisone) vs CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) as frontline treatment of PTCL, projecting that increasing use of frontline A+CHP will leads to more patients with PTCL alive and without disease progression in 2031.

October’s edition of Frontiers in Oncology features an article co-authored by two Curta researchers, Ashley Kang and Lisa Bloudek. The article summarizes a systematic literature review that identified studies which HER2 experssion is characterized in locally advanced unresectable or metastatic and earlier stage urothelial carcinoma.

Curta researchers are proud to introduce the Oncology Simulation Model (OSM), a novel model framework that combines and extends existing modeling practices into an innovative and dynamic simulation model to estimate prevalence and survival in oncology. This flexible framework can be leveraged to answer many research questions considering efficacy, treatment patterns, and sequencing.

The October issue of the American Journal of Clinical Dermatology features an article by several researchers from Curta. The article highlights how ruxolitinib cream treatment for patients with atopic dermatitis affects their work productivity and ability to engage in activities based on a post hoc analysis of pooled data from ruxolitinib phase III studies.